POLE2 and neoplasm: Close to half of the significant genes for intron SNVs each involved more than 10% of patients (Figure 1C), including DNA polymerase epsilon 2, accessory subunit POLE2, a gene for which knockdown has shown anti-tumor activity in vitro (24), with intronic SNVs involving 155 patients (Figure 2C).